Affimed Financial Statements From 2010 to 2025
| AFMD Stock | USD 1.06 0.06 6.00% |
Gross Profit | Market Capitalization | Enterprise Value Revenue 5.1997 | Revenue | Earnings Share (4.73) |
Affimed NV Total Revenue |
|
Check Affimed NV financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Affimed NV's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 1.8 M or Selling General Administrative of 29.8 M, as well as many indicators such as Price To Sales Ratio of 11.15, Dividend Yield of 0.0 or PTB Ratio of 1.87. Affimed financial statements analysis is a perfect complement when working with Affimed NV Valuation or Volatility modules.
Affimed | Select Account or Indicator |
Affimed NV Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Affimed NV Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Affimed NV Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Affimed NV Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Affimed Fundamental Market Drivers
| Cash And Short Term Investments | 72.9 M |
Affimed Upcoming Events
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 28th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
About Affimed NV Financial Statements
Affimed NV stakeholders use historical fundamental indicators, such as Affimed NV's revenue or net income, to determine how well the company is positioned to perform in the future. Although Affimed NV investors may analyze each financial statement separately, they are all interrelated. For example, changes in Affimed NV's assets and liabilities are reflected in the revenues and expenses on Affimed NV's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Affimed NV. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 711.9 K | 676.3 K | |
| Total Revenue | 9.5 M | 17.3 M | |
| Cost Of Revenue | 1.8 M | 1.1 M | |
| Stock Based Compensation To Revenue | 1.17 | 1.22 | |
| Sales General And Administrative To Revenue | 3.43 | 3.60 | |
| Research And Ddevelopement To Revenue | 10.33 | 10.84 | |
| Capex To Revenue | 0.41 | 0.43 | |
| Revenue Per Share | 0.50 | 0.47 | |
| Ebit Per Revenue | (11.60) | (11.02) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Affimed NV is a strong investment it is important to analyze Affimed NV's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Affimed NV's future performance. For an informed investment choice regarding Affimed Stock, refer to the following important reports:Check out the analysis of Affimed NV Correlation against competitors. For information on how to trade Affimed Stock refer to our How to Trade Affimed Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Affimed NV. If investors know Affimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Affimed NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.73) | Revenue Per Share | Quarterly Revenue Growth (0.92) | Return On Assets | Return On Equity |
The market value of Affimed NV is measured differently than its book value, which is the value of Affimed that is recorded on the company's balance sheet. Investors also form their own opinion of Affimed NV's value that differs from its market value or its book value, called intrinsic value, which is Affimed NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Affimed NV's market value can be influenced by many factors that don't directly affect Affimed NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Affimed NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Affimed NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Affimed NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.